From GlobeNewswire: 2025-05-15 02:07:00

A recent study published in PLOS One shows that the drug masitinib has promising neuroprotective effects, lowering serum neurofilament light chain levels, a key biomarker for neurodegenerative disorders like multiple sclerosis, ALS, and Alzheimer’s. Masitinib targets mast cells and microglia, potentially slowing neuronal damage and reducing inflammation. The study demonstrates masitinib’s ability to limit neuronal damage in a model of neuroimmune-driven neurodegenerative disease, offering hope for treating these conditions. With results showing a reduction in NfL levels and pro-inflammatory cytokines, masitinib presents a promising option for neurodegenerative diseases. AB Science is focusing on developing treatments for diseases with high unmet medical needs. Their lead compound, masitinib, is being developed for various human diseases. The company is based in Paris and listed on Euronext Paris. Forward-looking statements in their press release caution investors about potential risks and uncertainties. For more information, contact AB Science’s Financial Communication & Media Relations at [email protected].



Read more at GlobeNewswire: AB Science today reports a new publication in the